First AD

Second AD

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Pancreatic Cancer

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers

OncLive News Network®

The Tisch Cancer Institute at Mount Sinai 

Cancer Centers

Partner

Prevalence of NRG1 Fusions in Lung Cancer

Differences Between DNA and RNA Testing for NRG1

Standard Treatments for NRG1 Fusion+ NSCLC

Ongoing Research Efforts Targeting NRG1 in Lung Cancer

Efficacy With NRG1-Directed Agents in NSCLC

Prognosis, Rarity of NRG1+ Pancreatic Cancer

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

Standard Treatment Regimens for NRG1+ Pancreatic Cancer

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors